Biologics like monoclonal antibodies/nanobodies expand GPCR targeting, with Glucagon-Like Peptide-1 (GLP-1) agonist/Gastric Inhibitory Polypeptide (GIP) antagonist combos showing efficacy against obesity/diabetes (Gutgesell et al., 2024). Here, GIP is linked to obesity due to melanocortin 4 receptor deficiency.